Dr. Mario Rocci Joins The IMA Group as Strategic Advisor in Clinical Research

Share Article

The IMA Group announced today that industry veteran Dr. Mario Rocci has joined the company's Clinical Research division as its new Strategic Advisor. Dr. Rocci will help expand the company's office-based, decentralized and virtual clinical trials.

Mario Rocci, PhD, FCP, FFIP, a seasoned executive with 35 years of scientific and business management experience, has joined The IMA Group (IMA) as Strategic Advisor in the Clinical Research division.

IMA Clinical Research is a network of integrated research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA performs trials with a flexible model using both their physical locations and virtual capabilities that reach people around the country to support the advancement of safe and effective medication therapies. Additionally, IMA also maintains a robust study participant database to recruit and complete trials efficiently.

“Given the current international attention on clinical trials stemming from the COVID-19 pandemic, there is an increasing emphasis for quality, reputable research that can be delivered quickly,” said Mark Weinberger, PhD, MPH, President of IMA. “Mario shares our excitement for the growth of IMA through its unique network of sites and infrastructure. His extensive background in pharma, both in academia and industry, will greatly enhance IMA’s leadership team with greater visibility and standing in the field.”

Rocci has an extensive background in pharmaceutical sciences. As a trained pharmacist and pharmaceutical scientist, Rocci has been in the industry for over 40 years. Prior to joining IMA, he held executive leadership roles as President of ICON Development Solutions and as CEO of Prevalere Life Sciences. Dr. Rocci has published extensively during his career with more than 100 peer-reviewed articles. At IMA Clinical Research, he is responsible for assisting leadership with business and strategy development and growth initiatives.

“I look forward to joining an experienced clinical research team as we continue to grow into new therapeutic areas, expanded geographies, and bring on more diverse trial methodologies,” said Rocci. “IMA’s ability to offer office-based, decentralized and virtual trials through a hybrid model is truly cutting edge and I look forward to helping our clients bring promising new products and services to the market.”

Rocci holds a PhD in Pharmaceutical Sciences from the University at Buffalo, State University of New York (SUNY) and resides in Utica, NY.

About The IMA Group:
For over 30 years, The IMA Group, headquartered in Tarrytown, New York and with offices nation-wide, has been dedicated to helping people get back to work and resume productivity. Featuring three fully integrated divisions -- Government Services, Payer Services and Clinical Research – IMA has provided clinical evaluation and screening services to employers, payers and government agencies, as well as clinical research services to pharmaceutical sponsors and CROs. Over the past 10 years, IMA has conducted more than three million evaluations nationwide, utilizing thousands of providers based both at IMA’s 80+ offices as well as independent locations. For more information, visit http://www.theIMAgroup.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenna Harrington

Doug Markham
Visit website